HC Wainwright Has Lowered Expectations for GH Research (NASDAQ:GHRS) Stock Price

GH Research (NASDAQ:GHRS) had its price objective reduced by HC Wainwright from $70.00 to $65.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 199.82% from the stock’s current price.

Other research analysts also recently issued research reports about the company. Cantor Fitzgerald lifted their price target on GH Research from $25.00 to $35.00 and gave the company an “overweight” rating in a report on Friday. Citigroup restated an “outperform” rating on shares of GH Research in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research report on Tuesday, April 21st. Royal Bank Of Canada lifted their target price on GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Finally, Guggenheim set a $34.00 price target on shares of GH Research and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.38.

GH Research Stock Performance

GH Research stock opened at $21.68 on Tuesday. The company has a 50 day moving average price of $17.27 and a 200 day moving average price of $15.59. GH Research has a 52 week low of $10.66 and a 52 week high of $24.66. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -23.56 and a beta of 1.27.

GH Research (NASDAQ:GHRS) last announced its earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Equities analysts forecast that GH Research will post -1.52 earnings per share for the current fiscal year.

Institutional Trading of GH Research

A number of institutional investors have recently bought and sold shares of GHRS. Barclays PLC grew its stake in GH Research by 63.4% in the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after purchasing an additional 822 shares in the last quarter. North Star Investment Management Corp. purchased a new stake in shares of GH Research during the 1st quarter worth about $31,000. Royal Bank of Canada lifted its holdings in shares of GH Research by 43.1% during the 1st quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock valued at $36,000 after buying an additional 780 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of GH Research in the 4th quarter valued at approximately $38,000. Finally, Osaic Holdings Inc. grew its stake in shares of GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after buying an additional 2,400 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.